Dr. Frankfurt on the Future of AML Treatments

Olga Frankfurt, MD
Published: Monday, Oct 30, 2017



Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.


Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x